Intellia Therapeutics Inc
NASDAQ:NTLA
Balance Sheet
Balance Sheet Decomposition
Intellia Therapeutics Inc
Intellia Therapeutics Inc
Balance Sheet
Intellia Therapeutics Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
10
|
76
|
273
|
341
|
59
|
57
|
160
|
123
|
524
|
227
|
189
|
|
| Cash Equivalents |
10
|
76
|
273
|
341
|
59
|
57
|
160
|
123
|
524
|
227
|
189
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
255
|
223
|
437
|
625
|
669
|
685
|
412
|
|
| Total Receivables |
0
|
1
|
7
|
11
|
8
|
5
|
2
|
2
|
4
|
36
|
9
|
|
| Accounts Receivables |
0
|
1
|
7
|
11
|
8
|
5
|
2
|
2
|
4
|
36
|
9
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
2
|
4
|
3
|
5
|
17
|
19
|
20
|
50
|
30
|
|
| Total Current Assets |
10
|
78
|
281
|
355
|
325
|
290
|
617
|
769
|
1 217
|
998
|
640
|
|
| PP&E Net |
0
|
3
|
11
|
15
|
17
|
37
|
55
|
100
|
161
|
148
|
247
|
|
| PP&E Gross |
0
|
3
|
11
|
15
|
17
|
37
|
55
|
100
|
161
|
148
|
247
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
4
|
9
|
14
|
19
|
26
|
33
|
40
|
50
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
5
|
0
|
396
|
102
|
136
|
283
|
|
| Other Long-Term Assets |
0
|
2
|
7
|
6
|
5
|
3
|
5
|
30
|
41
|
18
|
22
|
|
| Total Assets |
11
N/A
|
82
+667%
|
299
+264%
|
376
+26%
|
347
-8%
|
334
-4%
|
676
+102%
|
1 295
+91%
|
1 520
+17%
|
1 301
-14%
|
1 191
-8%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
1
|
5
|
2
|
3
|
4
|
11
|
10
|
5
|
7
|
15
|
|
| Accrued Liabilities |
2
|
3
|
6
|
8
|
11
|
19
|
31
|
52
|
78
|
86
|
76
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
7
|
20
|
21
|
27
|
13
|
23
|
64
|
44
|
22
|
21
|
|
| Total Current Liabilities |
2
|
11
|
31
|
31
|
41
|
36
|
64
|
126
|
127
|
115
|
111
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
4
|
58
|
44
|
29
|
29
|
85
|
128
|
158
|
136
|
208
|
|
| Total Liabilities |
3
N/A
|
15
+377%
|
89
+502%
|
76
-15%
|
69
-8%
|
64
-7%
|
149
+132%
|
254
+70%
|
285
+12%
|
251
-12%
|
319
+27%
|
|
| Equity | ||||||||||||
| Common Stock |
17
|
89
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
10
|
22
|
54
|
121
|
201
|
301
|
435
|
703
|
1 177
|
1 658
|
2 177
|
|
| Additional Paid In Capital |
0
|
1
|
263
|
422
|
479
|
571
|
962
|
1 746
|
2 420
|
2 711
|
3 049
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
8
|
2
|
1
|
|
| Total Equity |
8
N/A
|
67
+787%
|
210
+211%
|
301
+43%
|
278
-8%
|
270
-3%
|
527
+95%
|
1 040
+97%
|
1 236
+19%
|
1 050
-15%
|
872
-17%
|
|
| Total Liabilities & Equity |
11
N/A
|
82
+667%
|
299
+264%
|
376
+26%
|
347
-8%
|
334
-4%
|
676
+102%
|
1 295
+91%
|
1 520
+17%
|
1 301
-14%
|
1 191
-8%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
35
|
35
|
36
|
42
|
45
|
50
|
66
|
75
|
87
|
93
|
102
|
|